Patients were stratified according to the presence/absence of the DRB1*15:01 allele risk, but no differences were found between those two MS groups when DRB1*03:01 data were analysed; therefore, all MS patients were combined (column “total” of Table 1) for case-control comparisons. This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.